151 related articles for article (PubMed ID: 29272443)
1. Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz.
Wallender E; Vucicevic K; Jagannathan P; Huang L; Natureeba P; Kakuru A; Muhindo M; Nakalembe M; Havlir D; Kamya M; Aweeka F; Dorsey G; Rosenthal PJ; Savic RM
J Infect Dis; 2018 Mar; 217(6):964-972. PubMed ID: 29272443
[TBL] [Abstract][Full Text] [Related]
2. Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda.
Wallender E; Zhang N; Conrad M; Kakuru A; Muhindo M; Tumwebaze P; Kajubi R; Mota D; Legac J; Jagannathan P; Havlir D; Kamya M; Dorsey G; Aweeka F; Rosenthal PJ; Savic RM
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530597
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention.
Kajubi R; Huang L; Jagannathan P; Chamankhah N; Were M; Ruel T; Koss CA; Kakuru A; Mwebaza N; Kamya M; Havlir D; Dorsey G; Rosenthal PJ; Aweeka FT
Clin Pharmacol Ther; 2017 Sep; 102(3):520-528. PubMed ID: 28187497
[TBL] [Abstract][Full Text] [Related]
4. Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine.
Savic RM; Jagannathan P; Kajubi R; Huang L; Zhang N; Were M; Kakuru A; Muhindo MK; Mwebaza N; Wallender E; Clark TD; Opira B; Kamya M; Havlir DV; Rosenthal PJ; Dorsey G; Aweeka FT
Clin Infect Dis; 2018 Sep; 67(7):1079-1088. PubMed ID: 29547881
[TBL] [Abstract][Full Text] [Related]
5. Piperaquine Exposure Is Altered by Pregnancy, HIV, and Nutritional Status in Ugandan Women.
Hughes E; Imperial M; Wallender E; Kajubi R; Huang L; Jagannathan P; Zhang N; Kakuru A; Natureeba P; Mwima MW; Muhindo M; Mwebaza N; Clark TD; Opira B; Nakalembe M; Havlir D; Kamya M; Rosenthal PJ; Dorsey G; Aweeka F; Savic RM
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 33020153
[TBL] [Abstract][Full Text] [Related]
6. Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women.
Hughes E; Wallender E; Kajubi R; Jagannathan P; Ochieng T; Kakuru A; Kamya MR; Clark TD; Rosenthal PJ; Dorsey G; Aweeka F; Savic RM
Clin Infect Dis; 2022 Aug; 75(3):406-415. PubMed ID: 34864925
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine.
Permala J; Tarning J; Nosten F; White NJ; Karlsson MO; Bergstrand M
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242661
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults.
Banda CG; Dzinjalamala F; Mukaka M; Mallewa J; Maiden V; Terlouw DJ; Lalloo DG; Khoo SH; Mwapasa V
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784846
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial.
Sevene E; Banda CG; Mukaka M; Maculuve S; Macuacua S; Vala A; Piqueras M; Kalilani-Phiri L; Mallewa J; Terlouw DJ; Khoo SH; Lalloo DG; Mwapasa V
Malar J; 2019 Aug; 18(1):277. PubMed ID: 31429785
[TBL] [Abstract][Full Text] [Related]
10. Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
Hughes E; Mwebaza N; Huang L; Kajubi R; Nguyen V; Nyunt MM; Orukan F; Mwima MW; Parikh S; Aweeka F
J Acquir Immune Defic Syndr; 2020 Feb; 83(2):140-147. PubMed ID: 31929402
[TBL] [Abstract][Full Text] [Related]
11. Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children.
Sundell K; Jagannathan P; Huang L; Bigira V; Kapisi J; Kakuru MM; Savic R; Kamya MR; Dorsey G; Aweeka F
Malar J; 2015 Sep; 14():368. PubMed ID: 26403465
[TBL] [Abstract][Full Text] [Related]
12. Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial.
Kajubi R; Ochieng T; Kakuru A; Jagannathan P; Nakalembe M; Ruel T; Opira B; Ochokoru H; Ategeka J; Nayebare P; Clark TD; Havlir DV; Kamya MR; Dorsey G
Lancet; 2019 Apr; 393(10179):1428-1439. PubMed ID: 30910321
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali.
Dama S; Niangaly H; Djimde M; Sagara I; Guindo CO; Zeguime A; Dara A; Djimde AA; Doumbo OK
Malar J; 2018 Oct; 17(1):347. PubMed ID: 30290808
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women.
Benjamin JM; Moore BR; Salman S; Page-Sharp M; Tawat S; Yadi G; Lorry L; Siba PM; Batty KT; Robinson LJ; Mueller I; Davis TM
Antimicrob Agents Chemother; 2015 Jul; 59(7):4260-71. PubMed ID: 25963981
[TBL] [Abstract][Full Text] [Related]
15. Efavirenz-Based Antiretroviral Therapy but Not Pregnancy Increased Unbound Piperaquine Exposure in Women during Malaria Chemoprevention.
Hong H; Aslam-Mir U; Kajubi R; Wallender E; Mwebaza N; Dorsey G; Rosenthal PJ; Aweeka FT; Huang L
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0142722. PubMed ID: 36916944
[TBL] [Abstract][Full Text] [Related]
16. Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Kakuru A; Jagannathan P; Muhindo MK; Natureeba P; Awori P; Nakalembe M; Opira B; Olwoch P; Ategeka J; Nayebare P; Clark TD; Feeney ME; Charlebois ED; Rizzuto G; Muehlenbachs A; Havlir DV; Kamya MR; Dorsey G
N Engl J Med; 2016 Mar; 374(10):928-39. PubMed ID: 26962728
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquine.
Zongo I; Somé FA; Somda SA; Parikh S; Rouamba N; Rosenthal PJ; Tarning J; Lindegardh N; Nosten F; Ouédraogo JB
PLoS One; 2014; 9(8):e103200. PubMed ID: 25133389
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria.
Lwin KM; Phyo AP; Tarning J; Hanpithakpong W; Ashley EA; Lee SJ; Cheah P; Singhasivanon P; White NJ; Lindegårdh N; Nosten F
Antimicrob Agents Chemother; 2012 Mar; 56(3):1571-7. PubMed ID: 22252804
[TBL] [Abstract][Full Text] [Related]
19. Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women.
Natureeba P; Ades V; Luwedde F; Mwesigwa J; Plenty A; Okong P; Charlebois ED; Clark TD; Nzarubara B; Havlir DV; Achan J; Kamya MR; Cohan D; Dorsey G
J Infect Dis; 2014 Dec; 210(12):1938-45. PubMed ID: 24958908
[TBL] [Abstract][Full Text] [Related]
20. Comparative Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Ugandan Children.
Yeka A; Wallender E; Mulebeke R; Kibuuka A; Kigozi R; Bosco A; Kyambadde P; Opigo J; Kalyesubula S; Senzoga J; Vinden J; Conrad M; Rosenthal PJ
J Infect Dis; 2019 Mar; 219(7):1112-1120. PubMed ID: 30418593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
